The U.S. Food and Drug Administration has approved daraxonrasib, a new targeted therapy for metastatic pancreatic cancer that doubled median survival time compared to chemotherapy in a phase 3 clinical trial. The drug, manufactured by Revolution Medicines and sold under the brand name Rasonque, represents a significant shift in how one of medicine’s most resistant cancers can be treated.
At a glance
- Daraxonrasib approval: The FDA cleared the drug for people with metastatic pancreatic cancer who have already undergone chemotherapy, making it the first major targeted therapy to clear that bar for this cancer type.
- Survival data: In the phase 3 trial, patients taking daraxonrasib had a median overall survival of 13.2 months, compared to 6.6 months for those receiving chemotherapy — a near-doubling across both the mutation-specific and full trial populations.
- KRAS mutation targeting: The drug works by blocking an activated KRAS protein that gets stuck in the “on” position, telling cancer cells to keep growing — a mechanism that may also open treatment pathways for other cancers driven by similar mutations.
Why this matters for a cancer with few answers
Pancreatic cancer has the lowest five-year survival rate of any major cancer — around 13 percent. It is typically diagnosed late, spreads quickly, and has long resisted treatment with standard chemotherapy. Tumors frequently stop responding or grow back even during active treatment, leaving patients with very limited options.
Daraxonrasib changes that picture in a meaningful way. Rather than bombarding cells with toxic agents, it targets a specific molecular driver of the disease. “Daraxonrasib is a targeted treatment, not chemotherapy,” said Kyaw Lwin Aung, a medical oncologist at Baptist Health Herbert Wertheim Cancer Institute, who was involved in the trial. “It works differently from chemotherapy by targeting activated KRAS protein in pancreatic cancer cells.”
Some patients in the trial lived for years — an outcome that is exceptionally rare in late-stage pancreatic cancer.
The trial behind the approval
The phase 3 trial enrolled 500 patients, most of whom carried specific cancer-driving gene mutations. All had previously treated metastatic pancreatic cancer. Participants were assigned to receive either daraxonrasib or chemotherapy.
Among patients with the targeted mutations, the daraxonrasib group had a median overall survival of 13.2 months. The chemotherapy group reached 6.6 months. Across the full trial population — including those without the mutations — the figures were nearly identical: 13.2 months versus 6.7 months. The consistency across both groups strengthened the case for broad approval.
The trial results were published earlier in 2026 C.E., and the FDA approval followed.
What comes next for KRAS-targeted therapy
Aung sees daraxonrasib as the start of a larger shift. “We can now envisage a future with no chemotherapy needed for pancreatic cancer patients. This is a remarkable milestone,” he said. He also noted that similar KRAS mutations appear in other cancer types, suggesting the same targeting approach could eventually be adapted for broader use. “This approval also opens up opportunities for KRAS-targeted treatments for those with other cancers. We will see significant advances in the near future in KRAS-targeted therapy for other cancer types.”
This approval is part of a wave of medical breakthroughs in recent years built on precision oncology — treatments that work by understanding the specific molecular behavior of a patient’s cancer rather than applying a one-size approach. The approach has already shown strong results in cancers like rectal cancer, where targeted immunotherapy has produced remarkable remission data.
Daraxonrasib is taken as two pills a day, making it a relatively accessible regimen for patients. The drug’s pricing has not yet been announced by Revolution Medicines, and cost remains a live question for access — a real limitation for any therapy that could otherwise reach a wide population. The FDA approval currently covers patients who have already received chemotherapy, meaning those newly diagnosed do not yet have this as a first-line option.
Still, the approval marks a clear turning point. Pancreatic cancer has long been treated as an area where medicine had largely run out of ideas. Daraxonrasib — and the KRAS-targeting science behind it — suggests that chapter may be closing. You can find more milestones like this one in the Good News for Humankind archive on public health wins.
Read more
For more on this story, see: Scientific American
For more from Good News for Humankind, see:
- FDA approves Journavx, the first new class of pain drug in decades
- Dostarlimab earns FDA breakthrough designation for rectal cancer
- The Good News for Humankind archive on cancer research
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
